Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 401–500 of 1,002
Spicer, J. F., Basu, B., Montes, A., Banerji, U., Kristeleit, R. S., Miller, R. E., Veal, G. J., Corrigan, C. J., Till, S. J., Figini, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39679-9 · Cited by 50
Delayed Anaphylaxis to Red Meat Masquerading as Idiopathic Anaphylaxis
Tripathi, A., Commins, S. P., Heymann, P. W., & Platts‐Mills, T. A. E. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.02.017 · Cited by 53
Self-citationKeating, K. N., Walko, C. M., Stephenson, B., O’Neil, B. H., & Weiss, J. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155213510542 · Cited by 49
Tharmalingam, T., Adamczyk, B., Doherty, M., Royle, L., & Rudd, P. M. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9443-9 · Cited by 48
Baker, M. G., & Sampson, H. A. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.01.027 · Cited by 52
α-Gal-Based Vaccines: Advances, Opportunities, and Perspectives
Hodžić, A., Mateos‐Hernández, L., de la Fuente, J., & Cabezas‐Cruz, A. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.08.001 · Cited by 52
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein
McCue, J. T., Kshirsagar, R., Selvitelli, K., Lü, Q., Zhang, M., Mei, B., Peters, R., Pierce, G. F., Dumont, J., Raso, S. W., et al. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.05.012 · Cited by 48
Chia, S., Tay, S. J., Song, Z., Yang, Y., Walsh, I., & Pang, K. T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114757 · Cited by 49
Sun, R., Qian, M. G., & Zhang, X. (2024) · mAbs · doi:10.1080/19420862.2024.2324836 · Cited by 49
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions
Vultaggio, A., Nencini, F., Pratesi, S., Petroni, G., Maggi, E., & Matucci, A. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0139 · Cited by 49
Bhattacharyya, S., Feferman, L., Unterman, T. G., & Tobacman, J. K. (2015) · Journal of Diabetes Research · doi:10.1155/2015/513429 · Cited by 47
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development
Salazar‐Fontana, L. I., Desai, D. D., Khan, T. A., Pillutla, R. C., Prior, S., Ramakrishnan, R., Schneider, J., & Joseph, A. M. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0030-z · Cited by 48
Canis, K., Anzengruber, J., Garénaux, E., Feichtinger, M., Benamara, K., Scheiflinger, F., Savoy, L.-A., Reipert, B. M., & Mališauskas, M. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14204 · Cited by 55
The Complex Clinical Picture of Side Effects to Biologicals
Hausmann, O. V., Seitz, M., Villiger, P. M., & Pichler, W. J. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.03.001 · Cited by 47
Approach to the Patient with Drug Allergy
Schnyder, B. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.04.005 · Cited by 47
Graf, T., Heinrich, K., Grunert, I., Wegele, H., Haberger, M., Bulau, P., & Leiss, M. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113251 · Cited by 46
Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity
Wolf, B., Piksa, M., Beley, I., Patoux, A., Besson, T., Cordier, V., Voedisch, B., Schindler, P. A., Stöllner, D., Perrot, L., et al. (2022) · Immunology · doi:10.1111/imm.13481 · Cited by 48
The bioactivity and fractionation of peptide hydrolysates in cultures of CHO cells
Spearman, M. A., Lodewyks, C. L., Richmond, M. E. I., & Butler, M. (2014) · Biotechnology Progress · doi:10.1002/btpr.1930 · Cited by 47
Stevens, W., Addo‐Yobo, E., Roper, J., Woodcock, A., James, H., Platts‐Mills, T., & Custovic, A. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03832.x · Cited by 45
Self-citationdel Val, I. J., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.09.005 · Cited by 45
Cytokine-targeting biologics for allergic diseases
Lawrence, M. G., Steinke, J. W., & Borish, L. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.01.009 · Cited by 48
Glycosylation of Therapeutic Proteins: A Critical Quality Attribute
Delobel, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1241-5_1 · Cited by 47
Modulating antibody effector functions by Fc glycoengineering
García-Alija, M., Moer, B. V., Sastre, D. E., Azzam, T., Du, J. J., Trastoy, B., Callewaert, N., Sundberg, E. J., & Guerin, M. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108201 · Cited by 47
Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis
Tanaka, H., Yang, G.-X., Iwakoshi, N., Knechtle, S. J., Kawata, K., Tsuneyama, K., Leung, P., Coppel, R. L., Ansari, A. A., Joh, T., et al. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12193 · Cited by 45
Lee, S. C., Kim, S., Park, K. H., Lee, J., & Park, J. (2019) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2019.11.5.723 · Cited by 46
Vultaggio, A., Perlato, M., Nencini, F., Vivarelli, E., Maggi, E., & Matucci, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765747 · Cited by 45
Rosenberg, Y. J., Saxena, A., Sun, W., Jiang, X., Chilukuri, N., Luo, C., Doctor, B. P., & Lee, K. D. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.02.042 · Cited by 45
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Burtness, B. A., & Faller, B. A. (2009) · Biologics · doi:10.2147/btt.2009.3546 · Cited by 45
Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)
Pintea, I., Petricău, C., Dumitraşcu, D. I., Muntean, A. M., Brănişteanu, D. C., Branisteanu, D. E., & Deleanu, D. M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10381 · Cited by 47
The role of antibody glycosylation in autoimmune and alloimmune kidney diseases
Beyze, A., Larroque, C., & Quintrec, M. L. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00850-0 · Cited by 45
Molecular allergy diagnosis: Status anno 2015
Gasse, A. L. V., Mangodt, E. A., Faber, M. A., Sabato, V., Bridts, C. H., & Ebo, D. G. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.02.012 · Cited by 50
Impact of cell culture on recombinant monoclonal antibody product heterogeneity
Liu, H., Nowak, C., Shao, M., Ponniah, G., & Neill, A. (2016) · Biotechnology Progress · doi:10.1002/btpr.2327 · Cited by 47
Hofheinz, R.-D., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.032 · Cited by 42
George, T. J., LaPlant, K. D., Walden, E. O., Davis, A. B., Riggs, C. E., Close, J., George, S. N., & Lynch, J. W. (2010) · PubMed · Cited by 44
Preparation and use of therapeutic antibodies primarily of human origin
Stiehm, E. R., Keller, M., & Vyas, G. N. (2008) · Biologicals · doi:10.1016/j.biologicals.2008.07.002 · Cited by 47
Saif, M. W., Peccerillo, J., & Potter, V. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0831-6 · Cited by 44
Cordy, J. M., Morley, P. J., Wright, T. J., Birchler, M., Lewis, A. P., Emmins, R., Chen, Y. Z., Powley, W. M., Bareille, P. J., Wilson, R., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12680 · Cited by 43
Immunologic Evaluation of Drug Allergy
Alcaide, E. G., Torres, M. J., Mayorga, C., & Blanca, M. (2012) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2012.4.5.251 · Cited by 46
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben‐Horin, S., Heap, G., Ahmad, T., Kim, H., Kwon, T., & Chowers, Y. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1091307 · Cited by 43
Where’s the Beef? Understanding Allergic Responses to Red Meat in Alpha-Gal Syndrome
Carson, A. S., Gardner, A., & Iweala, O. I. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100712 · Cited by 38
A desensitization protocol for the mAb cetuximab
Jerath, M. R., Kwan, M., Kannarkat, M., Mirakhur, B., Carey, L., Valgus, J. M., Platts‐Mills, T. A. E., & Tarrant, T. K. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.046 · Cited by 43
Self-citationAnti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 47
Maier, S., Chung, C. H., Morse, M. A., Platts‐Mills, T. A. E., Townes, L., Mukhopadhyay, P., Bhagavatheeswaran, P., Racenberg, J., & Trifan, O. C. (2014) · Cancer Medicine · doi:10.1002/cam4.333 · Cited by 45
Self-citationGuilloux, L., Morisset, M., Codréanu, F., Parisot, L., & Moneret‐Vautrin, D. A. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000189190 · Cited by 42
Glycoengineering of CHO Cells to Improve Product Quality
Wang, Q., Yin, B., Chung, C., & Betenbaugh, M. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6972-2_2 · Cited by 47
Self-citationMazor, R., Crown, D., Addissie, S., Jang, Y., Kaplan, G., & Pastan, I. H. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.91 · Cited by 42
Approach to the Patient with Drug Allergy
Schnyder, B. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.03.006 · Cited by 42
Brezski, R. J., Greenplate, A. R., Strake, B., & Jordan, R. E. (2011) · mAbs · doi:10.4161/mabs.3.6.18119 · Cited by 43
Hilliard, M., Alley, W. R., McManus, C. A., Yu, Y. Q., Hallinan, S., Gebler, J. C., & Rudd, P. M. (2017) · mAbs · doi:10.1080/19420862.2017.1377381 · Cited by 48
Galili, U. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.032 · Cited by 74
Expression of mammalian proteins for diagnostics and therapeutics: a review
Mark, J. K. K., Lim, C. S. Y., Nordin, F., & Tye, G. J. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07651-3 · Cited by 48
Regulation of the Immune Response to α-Gal and Vector-borne Diseases
Cabezas‐Cruz, A., Mateos‐Hernández, L., Pérez-Cruz, M., Valdés, J. J., de Mera, I. G. F., Villar, M., & de la Fuente, J. (2015) · Trends in Parasitology · doi:10.1016/j.pt.2015.06.016 · Cited by 43
Talotta, R., Rucci, F., Canti, G. L., & Scaglione, F. (2019) · Immunotherapy · doi:10.2217/imt-2018-0081 · Cited by 43
Insect cells for antibody production: Evaluation of an efficient alternative
Palmberger, D., Rendić, D., Tauber, P., Krammer, F., Wilson, I. B. H., & Grabherr, R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.02.009 · Cited by 48
Characterization of anti-natalizumab antibodies in multiple sclerosis patients
Lundkvist, M., Engdahl, E., Holmén, C., Movérare, R., Olsson, T. P., Hillert, J. A., & Fogdell‐Hahn, A. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512462920 · Cited by 41
Kwon, O.-S., Joung, J., Park, Y., Kim, C., & Hong, S. H. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.04.005 · Cited by 45
Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E–Mediated Anaphylaxis
Pointreau, Y., Commins, S. P., Calais, G., Watier, H., & Platts‐Mills, T. A. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4701 · Cited by 42
Self-citationCarbohydrates as food allergens
Soh, J. Y., Huang, C. H., & Lee, B. W. (2015) · Asia Pacific Allergy · doi:10.5415/apallergy.2015.5.1.17 · Cited by 45
Alpha-Gal IgE Prevalence Patterns in the United States: An Investigation of 3,000 Military Recruits
Ailsworth, S. M., Susi, A., Workman, L. J., Ji, Y.-S., Patel, J., Nelson, M. R., Platts‐Mills, T. A. E., Nylund, C. M., & Wilson, J. M. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.10.046 · Cited by 42
Self-citationPlatts‐Mills, T. A. E., Gangwar, R. S., Workman, L. J., & Wilson, J. M. (2025) · Immunological Reviews · doi:10.1111/imr.70035 · Cited by 43
Self-citationXue, L., Fiscella, M., Rajadhyaksha, M., Goyal, J., Holland, C., Gorovits, B., & Morimoto, A. M. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9492-4 · Cited by 39
N-glycan analysis of human α1-antitrypsin produced in Chinese hamster ovary cells
Lee, K. J., Lee, S. M., Gil, J. Y., Kwon, O., Kim, J. Y., Park, S. J., Chung, H.-S., & Oh, D. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9453-7 · Cited by 41
The discovery of IgE 50 years later
Platts‐Mills, T. A. E., Heymann, P. W., Commins, S. P., & Woodfolk, J. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.01.003 · Cited by 43
Self-citationTo serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity
Hartholt, R. B., van Velzen, A. S., Peyron, I., ten Brinke, A., Fijnvandraat, K., & Voorberg, J. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.07.001 · Cited by 40
Spatial distribution of alpha-gal in Ixodes ricinus – A histological study
Fischer, J., Riel, S., Fehrenbacher, B., Frank, A., Schaller, M., Biedermann, T., Hilger, C., & Mackenstedt, U. (2020) · Ticks and Tick-borne Diseases · doi:10.1016/j.ttbdis.2020.101506 · Cited by 44
IgE Antibodies against Cancer: Efficacy and Safety
Chauhan, J., McCraw, A. J., Nakamura, M., Osborn, G., Sow, H. S., Cox, V. F., Stavraka, C., Josephs, D. H., Spicer, J. F., Karagiannis, S. N., et al. (2020) · Antibodies · doi:10.3390/antib9040055 · Cited by 40
Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis
Brusch, A. M., Clarke, R. C., Platt, P. R., & Phillips, E. J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12290 · Cited by 41
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma
Sundvall, M., Karrila, A., Nordberg, J., Grenman, R. A., & Elenius, K. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728211003716442 · Cited by 40
Schwickart, M., Vainshtein, I., Lee, R., Schneider, A. K., & Liang, M. (2014) · Bioanalysis · doi:10.4155/bio.14.127 · Cited by 38
Schwartzberg, L. S., Stepanski, E. J., Walker, M. S., Mathias, S. D., Houts, A. C., & Fortner, B. V. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0474-5 · Cited by 38
First-dose anaphylaxis to infliximab: a case of mammalian meat allergy
Chitnavis, M. V., Stein, D. J., Commins, S. P., Schuyler, A. J., & Behm, B. W. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.04.044 · Cited by 38
Idiopathic anaphylaxis yardstick
Carter, M. C., Akin, C., Castells, M., Scott, E. P., & Lieberman, P. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.08.024 · Cited by 41
A Peculiar Cause of Anaphylaxis: No More steak?
Wolver, S. E., Sun, D. R., Commins, S. P., & Schwartz, L. B. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2144-z · Cited by 48
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Allergie auf Säugetierfleisch: α-Gal: Neues Epitop, neue Entität?
Jappe, U. (2012) · Der Hautarzt · doi:10.1007/s00105-011-2266-y · Cited by 40
Prevalence and Impact of Type I Sensitization to Alpha-Gal in Patients Consulting an Allergy Unit
Fischer, J., Huynh, H.-N., Hebsaker, J., Forchhammer, S., & Yazdi, A. S. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000503966 · Cited by 39
Yoo, E. M., Yu, L. J., Wims, L. A., Goldberg, D. T., & Morrison, S. L. (2010) · mAbs · doi:10.4161/mabs.2.3.11802 · Cited by 42
Gülşen, A., Wedi, B., & Jappe, U. (2020) · Allergo Journal · doi:10.1007/s15007-020-2550-1 · Cited by 36
Wilson, J. M., Keshavarz, B., Retterer, M. K. C., Workman, L. J., Schuyler, A. J., McGowan, E. C., Lane, C. J., Kandeel, A., Purser, J., Rönmark, E., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.034 · Cited by 39
Self-citationCorbin, J. M., McNulty, M. J., Macharoen, K., McDonald, K. A., & Nandi, S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27475 · Cited by 36
The Who, What, Where, When, Why, and How of Drug Desensitization
Yang, B. C., & Castells, M. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.12.004 · Cited by 41
Etiology and Pathogenesis of Adverse Drug Reactions
Hausmann, O. V., Schnyder, B., & Pichler, W. J. (2012) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000335614 · Cited by 45
Grenon, N. N., & Chan, J. A.-W. (2009) · Clinical journal of oncology nursing · doi:10.1188/09.cjon.285-296 · Cited by 40
Ebo, D. G., Faber, M. A., Sabato, V., Leysen, J., Gadisseur, A., Bridts, C. H., & Clerck, L. D. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3278 · Cited by 38
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Arnold, D., & Misbah, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc080834 · Cited by 36
Fan, L., Frye, C. C., & Racher, A. J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.56 · Cited by 35
Desensitizations for Chemotherapy and Monoclonal Antibodies: Indications and Outcomes
Blatman, K. S. H., & Castells, M. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0453-5 · Cited by 36
Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines
Mimura, Y., Kelly, R. M., Unwin, L., Albrecht, S., Jefferis, R., Goodall, M., Mizukami, Y., Mimura-Kimura, Y., Matsumoto, T., Ueoka, H., et al. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.11.009 · Cited by 35
Humanizing glycosylation pathways in eukaryotic expression systems
Khan, A. H., Bayat, H., Rajabibazl, M., Sabri, S., & Rahimpour, A. (2016) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-016-2172-7 · Cited by 37
Salama, A., Evanno, G., Lim, N., Rousse, J., Berre, L. L., Nicot, A. B., Bach, J., Brouard, S., Harris, K. M., Ehlers, M. R., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001686 · Cited by 35
Glycoengineering of Mammalian Expression Systems on a Cellular Level
Heffner, K. M., Wang, Q., Hızal, D. B., Can, Ö., & Betenbaugh, M. J. (2018) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_57 · Cited by 40
Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics
Bavbek, S., Kendirlinan, R., Çerçi, P., Altıner, S., Soyyiğit, Ş., Sözener, Z. Ç., Aydın, Ö., & Gümüşburun, R. (2016) · International Archives of Allergy and Immunology · doi:10.1159/000454808 · Cited by 37
Engineering protein glycosylation in prokaryotes
Keys, T. G., & Aebi, M. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.05.016 · Cited by 36
Safety of Infusing Ipilimumab Over 30 Minutes
Momtaz, P., Park, V., Panageas, K. S., Postow, M. A., Callahan, M. K., Wolchok, J. D., & Chapman, P. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.0030 · Cited by 35
Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC
Ng, T. L., Narasimhan, N. I., Gupta, N., Venkatakrishnan, K., Kerstein, D., & Camidge, D. R. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.011 · Cited by 34
Tatarewicz, S. M., Mytych, D. T., Manning, M. S., Swanson, S. J., Moxness, M. S., & Chirmule, N. B. (2014) · Bioanalysis · doi:10.4155/bio.14.114 · Cited by 34
Hamm, M., Wang, Y., & Rustandi, R. R. (2013) · Pharmaceuticals · doi:10.3390/ph6030393 · Cited by 38
Steinke, J. W., Pochan, S. L., James, H. R., Platts-Mills, T. A. E., & Commins, S. P. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.021 · Cited by 34
Self-citationDrug hypersensitivity in the fast lane
Jakubovic, B. D., Vecillas, L. D. L., Jimenez-Rodriguez, T. W., Sanchez-Sanchez, S., & Castells, M. (2020) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.04.005 · Cited by 33
Biochemical and biophysical characterization of humanized IgG1 produced inPichia pastoris
Ha, S., Wang, Y., & Rustandi, R. R. (2011) · mAbs · doi:10.4161/mabs.3.5.16891 · Cited by 34
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.